Dishman Pharmaceuticals and Chemicals, a Rs.1,589 crore pharma company, has posted consolidated net profit growth of 9.4 per cent during the second quarter ended September 2015 to Rs.36.50 crore as against Rs.33.36 crore in the similar period of last year. However, its consolidated net sales declined by 4.8 per cent to Rs.373.66 crore from Rs.392.32 crore. EPS improved slightly to Rs.4.52 from Rs.4.13 in the last period. Its EBIDTA improved by 11.6 per cent to Rs.99.11 crore from Rs.88.80 crore. Interest cost went up sharply by 34.8 per cent to Rs.23.59 crore from Rs.17.50 crore.

After the announcement of financial working for the quarter, Dishman scrip declined by Rs.15.05 in the afternoon session to Rs.347 on BSE.

For the first half ended September 2015, Dishman's consolidated net sales improved marginally by 2.6 per cent to Rs.774 crore from Rs.754 crore in the same period of last year. Its consolidated net profit went up by 29.9 per cent to Rs.74.26 crore from Rs.57.17 crore. Its sales from CRAMS activities improved only by 0.2 per cent to Rs.521.55 crore from Rs.520.60 crore and that from other activities improved by 8.1 per cent to Rs.252.15 crore from Rs.233.28 crore.

Its standalone net sales for the nine months period ended September 2015 stood at Rs.231 crore as against Rs.199 crore, a growth of 16.1 per cent and its standalone net profit touched to Rs.47.85 crore as compared to Rs.26.96 crore.